1 Surgery Unit, UCL Institute of Child Health , London, United Kingdom .
Tissue Eng Part B Rev. 2013 Dec;19(6):503-15. doi: 10.1089/ten.TEB.2013.0120. Epub 2013 Jul 3.
Tissue-engineered skeletal muscle is urgently required to treat a wide array of devastating congenital and acquired conditions. Selection of the appropriate cell type requires consideration of several factors which amongst others include, accessibility of the cell source, in vitro myogenicity at high efficiency with the ability to maintain differentiation over extended periods of time, susceptibility to genetic manipulation, a suitable mode of delivery and finally in vivo differentiation giving rise to restoration of structural morphology and function. Potential stem-progenitor cell sources include and are not limited to satellite cells, myoblasts, mesoangioblasts, pericytes, muscle side-population cells, CD133(+) cells, in addition to embryonic stem cells, mesenchymal stem cells, amniotic fluid stem cells and induced pluripotent stem (iPS) cells. The relative merits and inherent limitations of these cell types within the field of tissue-engineering are discussed in the light of current research. Recent advances in the field of iPS cells should bear the fruits for some exciting developments within the field in the forthcoming years.
组织工程化骨骼肌对于治疗广泛的毁灭性先天性和获得性疾病非常重要。选择合适的细胞类型需要考虑多个因素，包括细胞来源的可及性、高效的体外成肌能力、能够在较长时间内维持分化、易于基因操作、合适的输送方式以及最终的体内分化，从而导致结构形态和功能的恢复。潜在的干细胞-祖细胞来源包括但不限于卫星细胞、成肌细胞、中胚层血管母细胞、周细胞、肌肉侧群细胞、CD133(+)细胞，以及胚胎干细胞、间充质干细胞、羊水干细胞和诱导多能干细胞(iPS 细胞)。本文结合当前的研究，讨论了这些细胞类型在组织工程领域中的相对优点和固有局限性。iPS 细胞领域的最新进展，应该会在未来几年为该领域的一些令人兴奋的发展带来成果。
